Skip to main content
AstraZeneca PLC logo

AstraZeneca PLC — Investor Relations & Filings

Ticker · AZN ISIN · GB0009895292 LEI · PY6ZZQWO2IZFZC3IOL08 IL Manufacturing
Open in API
Filings indexed 3,411 across all filing types
Latest filing 2024-02-22 Capital/Financing Update
Country GB United Kingdom
Listing IL AZN

About AstraZeneca PLC

https://www.astrazeneca.com/

AstraZeneca PLC is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company's portfolio is concentrated on several main therapy areas, including Oncology; Cardiovascular, Renal & Metabolism; and Respiratory & Immunology. AstraZeneca is committed to advancing healthcare through a robust research and development pipeline, aiming to deliver innovative medicines that address significant unmet medical needs for millions of patients worldwide. The company leverages scientific innovation to transform the future of healthcare and improve patient outcomes.

Recent filings

Filing Released Lang Actions
AstraZeneca PLC;AstraZeneca Finance LLC - Supplementary Prospectus
Capital/Financing Update Classification · 95% confidence The document is explicitly titled a "PROSPECTUS SUPPLEMENT DATED 20 FEBRUARY 2024 TO THE BASE PROSPECTUS DATED 15 JUNE 2023". It discusses the Programme established under the UK Prospectus Regulation and is approved by the Financial Conduct Authority. The primary purpose is to incorporate by reference parts of the company's Annual Report and Form 20-F Information 2023. A prospectus supplement is a document used in connection with the offering of securities, which falls under financing/capital activities, but more specifically, it is a regulatory document related to the offering structure. Given the options, this document relates to the structure of debt issuance (Euro Medium Term Note Programme) and incorporates financial data. It is not a standard 10-K, ER, or IR. Since it is a formal legal document related to capital raising/debt issuance, 'Capital/Financing Update' (CAP) is the most appropriate fit, as it supplements the base prospectus for the EMTN Programme. It is a formal regulatory filing related to financing.
2024-02-22 English
DIRECTOR/PDMR SHAREHOLDING
Director's Dealing Classification · 95% confidence The document is a Form 6-K filed by AstraZeneca PLC, reporting a transaction by a Person Discharging Managerial Responsibilities (PDMR), specifically the acquisition of shares by the CEO due to vesting under an investment plan. The content focuses on insider shareholding details and complies with EU Market Abuse Regulation disclosure requirements. There are no financial statements, earnings data, or management discussion of results. The document is a regulatory announcement about insider share transactions, which fits the definition of Director's Dealing (DIRS). The document length is about 5,089 characters, which is sufficient for a detailed insider transaction report. Therefore, the correct classification is DIRS with high confidence.
2024-02-22 English
Director/PDMR Shareholding
Director's Dealing Classification · 100% confidence The document is an official notification released via RNS (RNS Number: 9865D) concerning a 'Transaction by Person Discharging Managerial Responsibilities' (PDMR). Specifically, it details the vesting of shares under the AstraZeneca Investment Plan (AZIP) to the CEO, Pascal Soriot, and reports the acquisition of 12,345 Ordinary Shares. This type of insider transaction reporting, mandated by regulations like the EU Market Abuse Regulation (MAR), falls under the category of Director's Dealing (DIRS) or, more broadly, a regulatory announcement. Since the document explicitly details personal share transactions by an executive director, the most specific classification is 'Director's Dealing' (DIRS). Although it is published via RNS, DIRS is a more precise fit than the general 'RNS' fallback.
2024-02-22 English
AstraZeneca prices a $5bn bond offering
Capital/Financing Update Classification · 98% confidence The document is a formal announcement disseminated via RNS (RNS Number: 0127E) on February 22, 2024, detailing the pricing of a $5bn bond offering by AstraZeneca Finance LLC. This announcement concerns a significant financing activity (issuing debt securities) and mentions registration with the SEC on Form F-3. This clearly falls under the category of updates on company fundraising or capital structure changes. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document is short and acts as an announcement, but the specific nature of the content (bond pricing details) makes CAP more precise than the general RPA or RNS fallback.
2024-02-22 English
FWP
Capital/Financing Update Classification · 100% confidence The document is titled 'Free Writing Prospectus filed pursuant to Rule 433' and relates to a Preliminary Prospectus Supplement and Prospectus for a debt offering by AstraZeneca Finance LLC. It details terms of multiple senior notes offerings, including principal amounts, coupon rates, maturity dates, redemption provisions, underwriting discounts, and other financing details. The content is focused on the issuance of debt securities and the associated capital raising terms. There is no indication that this is a full annual or interim financial report, audit report, or earnings release. It is not a regulatory filing in the sense of officer certifications or miscellaneous announcements, nor is it a report publication announcement. The document is clearly a capital markets disclosure related to financing activities. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length (over 12,000 characters) and detailed financial terms support this classification with high confidence.
2024-02-22 English
424B2
Capital/Financing Update Classification · 100% confidence The document is a prospectus supplement and accompanying prospectus for a debt securities offering by AstraZeneca PLC and AstraZeneca Finance LLC. It includes detailed information about the terms of the notes, risk factors, use of proceeds, indebtedness and capitalization, description of notes, taxation, underwriting, and legal matters. It references incorporation by reference of the company's Annual Report on Form 20-F and other SEC filings. The document is a formal offering document related to capital raising and financing activities, not a financial report, earnings release, or management discussion. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial (15,000 characters), indicating it is the full prospectus supplement and not merely an announcement of a report.
2024-02-21 English

Browse filings by year

34 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.